CNPY3 and cancer: Our study demonstrated that CNPY3, a cochaperone of immune chaperone GRP94, was elevated in the majority of human cancers, and the overexpression of CNPY3 and GRP94 predicts an aggressive phenotype and poor clinical outcome.